Skip to main content

Table 3 Skeletal-related events in patients developing bone metastases during the five year study period

From: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Ā 

Clodronate

Placebo

Total number of patients

530

539

Skeletal-related event

Ā Ā 

ā€ƒā€ƒā€ƒConfirmed bone metastases

51 (9.6%) % of bone

73 (13.5%) % of bone

ā€ƒā€ƒā€ƒRadiation therapy

24 (4.5%) (48%)

47 (8.7%) (69%)

ā€ƒā€ƒā€ƒNon-vertebral fracture

6 (1.1%) (2%)

16 (2.9%) (22%)

ā€ƒā€ƒā€ƒVertebral fracture

6 (1.1%) (2%)

14 (2.6%) (19%)

ā€ƒā€ƒā€ƒHypercalcemia

3 (0.5%) (1%)

11 (2.0%) (15%)

ā€ƒā€ƒā€ƒSpinal cord compression

2 (0.4%) (1%)

5 (0.9%) (7%)

ā€ƒā€ƒā€ƒBone surgery

1 (0.2%) (1%)

4 (0.7%) (5%)

Overall for 5 year study period1 (any skeletal event)

29 (5.5%) (0.4%)

53 (9.8%) (73%)

  1. 1P < 0.01 versus placebo.